| 1 |
34162179 |
10.3324/haematol.2021.278743 |
2022 |
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas. |
MTOR |
| 2 |
34624079 |
10.1182/blood.2021012081 |
2022 |
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. |
MTOR |
| 3 |
34714908 |
10.1182/bloodadvances.2021005486 |
2022 |
Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. |
MTOR |
| 4 |
34791836 |
10.1002/cam4.4422 |
2022 |
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. |
MTOR |
| 5 |
35031886 |
10.1186/s43556-021-00066-9 |
2022 |
Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma. |
MTOR |
| 6 |
35035775 |
10.18632/oncotarget.28177 |
2022 |
GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells. |
MTOR |
| 7 |
35058488 |
10.1038/s41598-022-04916-6 |
2022 |
Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma. |
MTOR |
| 8 |
35068379 |
10.1080/16078454.2021.2019363 |
2022 |
Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma. |
MTOR |
| 9 |
35091546 |
10.1038/s41420-022-00833-9 |
2022 |
Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma. |
MTOR |
| 10 |
35257981 |
10.1016/j.drup.2022.100822 |
2022 |
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. |
MTOR |
| 11 |
35381283 |
10.1016/j.ijbiomac.2022.03.212 |
2022 |
Molecular characterization, expression and anti-tumor function analysis of yak IFITM2 gene. |
MTOR |
| 12 |
35558005 |
10.1177/17588359221093745 |
2022 |
Novel insights into the biomarkers and therapies for primary central nervous system lymphoma. |
MTOR |
| 13 |
35640776 |
10.1016/j.lfs.2022.120675 |
2022 |
Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis. |
MTOR |
| 14 |
35774848 |
10.1155/2022/3276925 |
2022 |
Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. |
MTOR |
| 15 |
35857791 |
10.1080/15548627.2022.2100105 |
2022 |
Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis. |
MTOR |
| 16 |
35908982 |
10.1016/j.blre.2022.100992 |
2022 |
Follicular lymphoma: The long and winding road leading to your cure? |
MTOR |
| 17 |
32749680 |
10.1002/jcp.29943 |
2021 |
Light-emitting diode irradiation induces AKT/mTOR-mediated apoptosis in human pancreatic cancer cells and xenograft mouse model. |
MTOR |
| 18 |
32970929 |
10.1111/ajco.13449 |
2021 |
Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. |
MTOR |
| 19 |
33393503 |
10.1172/JCI133090 |
2021 |
BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors. |
MTOR |
| 20 |
33567641 |
10.3390/cancers13040682 |
2021 |
Genomic Landscape of Hodgkin Lymphoma. |
MTOR |
| 21 |
33812443 |
10.19746/j.cnki.issn.1009-2137.2021.02.052 |
2021 |
[New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review]. |
MTOR |
| 22 |
34139193 |
10.1016/j.ajpath.2021.06.004 |
2021 |
Rictor/Mammalian Target of Rapamycin Complex 2 Signaling Protects Colonocytes from Apoptosis and Prevents Epithelial Barrier Breakdown. |
MTOR |
| 23 |
34159086 |
10.21037/tau-21-280 |
2021 |
The protective effects of exogenous spermine on renal ischemia-reperfusion injury in rats. |
MTOR |
| 24 |
34219464 |
10.1139/bcb-2021-0045 |
2021 |
Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway. |
MTOR |
| 25 |
34277781 |
10.21037/atm-21-2574 |
2021 |
A novel peptide promotes human trophoblast proliferation and migration through PI3K/Akt/mTOR signaling pathway. |
MTOR |
| 26 |
34426436 |
10.1158/1078-0432.CCR-21-0573 |
2021 |
Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. |
MTOR |
| 27 |
34557659 |
10.1016/j.isci.2021.102931 |
2021 |
The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma. |
MTOR |
| 28 |
34606736 |
10.1080/14728222.2021.1988927 |
2021 |
Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma. |
MTOR |
| 29 |
34651869 |
10.1002/hon.2933 |
2021 |
The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. |
MTOR |
| 30 |
34669944 |
10.1093/mtomcs/mfab058 |
2021 |
Maternal selenium deficiency suppresses proliferation, induces autophagy dysfunction and apoptosis in the placenta of mice. |
MTOR |
| 31 |
34710755 |
10.1016/j.phymed.2021.153802 |
2021 |
Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo. |
MTOR |
| 32 |
34736967 |
10.1016/j.ejphar.2021.174612 |
2021 |
Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells. |
MTOR |
| 33 |
34750354 |
10.1038/s41419-021-04353-9 |
2021 |
Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies. |
MTOR |
| 34 |
34796352 |
10.5187/jast.2021.e93 |
2021 |
Enhanced supply of methionine regulates protein synthesis in bovine mammary epithelial cells under hyperthermia condition. |
MTOR |
| 35 |
31774199 |
10.15252/embj.2019102030 |
2020 |
Paracaspase MALT1 regulates glioma cell survival by controlling endo-lysosome homeostasis. |
MTOR |
| 36 |
31774495 |
10.1182/blood.2019001904 |
2020 |
Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. |
MTOR |
| 37 |
31883669 |
10.1016/j.pathol.2019.09.014 |
2020 |
The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma. |
MTOR |
| 38 |
32127939 |
10.7150/jca.34981 |
2020 |
Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma <i>in vivo and vitro</i>. |
MTOR |
| 39 |
32179489 |
10.1016/j.cancergen.2020.02.005 |
2020 |
Integrating transcriptome-wide association study and copy number variation study identifies candidate genes and pathways for diffuse non-Hodgkin's lymphoma. |
MTOR |
| 40 |
32586008 |
10.3390/biomedicines8060170 |
2020 |
ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. |
MTOR |
| 41 |
32702393 |
10.1016/j.exphem.2020.07.005 |
2020 |
DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells. |
MTOR |
| 42 |
32926124 |
10.1182/bloodadvances.2020001685 |
2020 |
Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. |
MTOR |
| 43 |
33053749 |
10.3390/cancers12102936 |
2020 |
The In Vitro and In Vivo Anticancer Properties of Chalcone Flavokawain B through Induction of ROS-Mediated Apoptotic and Autophagic Cell Death in Human Melanoma Cells. |
MTOR |
| 44 |
33109547 |
10.21873/anticanres.14630 |
2020 |
Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells. |
MTOR |
| 45 |
33154951 |
10.3389/fonc.2020.591577 |
2020 |
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. |
MTOR |
| 46 |
30413649 |
10.1158/1535-7163.MCT-18-0478 |
2019 |
Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. |
MTOR |
| 47 |
30720463 |
10.1172/JCI98288 |
2019 |
Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR. |
MTOR |
| 48 |
31262977 |
10.1042/BSR20182274 |
2019 |
EPHA3 enhances macrophage autophagy and apoptosis by disrupting the mTOR signaling pathway in mice with endometriosis. |
MTOR |
| 49 |
31334109 |
10.3389/fonc.2019.00568 |
2019 |
Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells. |
MTOR |
| 50 |
31391255 |
10.1074/jbc.RA119.009551 |
2019 |
Coordinated regulation of scaffold opening and enzymatic activity during CARD11 signaling. |
MTOR |
| 51 |
31619091 |
10.1080/17474086.2020.1681962 |
2019 |
Contemporary management of nodal and primary splenic marginal zone lymphoma. |
MTOR |
| 52 |
28952842 |
10.1080/10428194.2017.1379077 |
2018 |
Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma. |
MTOR |
| 53 |
29399633 |
10.1126/sciadv.aar5701 |
2018 |
Discrete roles and bifurcation of PTEN signaling and mTORC1-mediated anabolic metabolism underlie IL-7-driven B lymphopoiesis. |
MTOR |
| 54 |
29483509 |
10.1038/s41467-018-03028-y |
2018 |
Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL. |
MTOR |
| 55 |
29925955 |
10.1038/s41586-018-0290-0 |
2018 |
A multiprotein supercomplex controlling oncogenic signalling in lymphoma. |
MTOR |
| 56 |
29937999 |
10.18632/oncotarget.25463 |
2018 |
Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. |
MTOR |
| 57 |
30104685 |
10.1038/s41598-018-30509-3 |
2018 |
Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma. |
MTOR |
| 58 |
30196309 |
10.12659/MSM.909726 |
2018 |
Marsdenia Tenacissima Extract Inhibits Proliferation and Promotes Apoptosis in Human Ovarian Cancer Cells. |
MTOR |
| 59 |
30231317 |
10.1200/EDBK_200829 |
2018 |
Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules. |
MTOR |
| 60 |
30305939 |
10.1136/esmoopen-2018-000387 |
2018 |
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. |
MTOR |
| 61 |
30360879 |
10.1053/j.seminoncol.2018.07.005 |
2018 |
New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs. |
MTOR |
| 62 |
28864640 |
10.1158/2159-8290.CD-17-0714 |
2017 |
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap. |
MTOR |
| 63 |
32300390 |
10.14740/jh320w |
2017 |
Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes. |
MTOR |
| 64 |
27147575 |
10.18632/oncotarget.9061 |
2016 |
Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. |
MTOR |
| 65 |
25909227 |
10.18632/oncotarget.3729 |
2015 |
MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. |
MTOR |
| 66 |
24970801 |
10.18632/oncotarget.2071 |
2014 |
Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. |
MTOR |
Datasets
Models
